Hims & Hers Health shares have surged 32.4% since Tuesday's session open. The stock is gaining following a standout ...

Investors are worried Novo Nordisk's competition with Eli Lilly is heating up and that the first-to-market GLP-1 leader is ...

Hims & Hers Health, Inc. (HIMS) could be a solid addition to your portfolio given a notable revision in the company's ...

Novo Nordisk reports its results in Danish kroner (DKK) rather than U.S. dollars. Sales grew 19% year over year to 78.1 ...

Hims & Hers Health (NYSE:HIMS) reported first-quarter earnings on Monday after the market closed and rocketed 18% after ...

Hims & Hers reports 111% YoY sales growth & 70%+ gross margin. Discover their growth potential, risks, & why it's a Buy ...

Hims & Hers ( HIMS 19.03%) stock soared 18.2% in trading on Tuesday after the company reported first-quarter revenue growth ...

Novo Nordisk says it's now cutting its annual outlook - seeing sales growth, at constant exchange rates, between 13% and 21%, vs. its previous forecast of 16% to 24%, and operating profit growth ...

The stock of Hims & Hers Health Inc. (HIMS) fell more than 4% in after-hours trading after the telehealth company issued ...

TOKYO (Reuters) - Robust demand for hybrids is expected to underpin steady profits at Toyota when the world’s top automaker ...

Palantir Technologies shares are down nearly 8% after the software group's stellar earnings could not prevent some profit taking after the stock's strong rally to near record highs.

Hims stock crumbled Tuesday after the telehealth platform issued a lackluster outlook for the current three-month period.